New insight into drug resistance in metastatic melanoma

by Alison Barbuti

(Medical Xpress)—A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.

Their findings suggest that using a combination of targeted therapies may be a more effective approach in the clinic.

Melanoma is a form of that develops from – the pigment-producing cells in skin. Advanced metastatic – where the cancer has spread throughout the body – is associated with poor survival, so new treatments are urgently needed.

In about 50% of melanoma cases, the tumour contains a mutation in a gene known as BRAF. Drugs that target BRAF – such as vemurafenib – have increased survival in patients with this mutation. However, many of these patients go on to develop resistance to treatment and their disease returns.

Now researchers from the Cancer Research UK Manchester Institute at The University of Manchester – part of the Manchester Cancer Research Centre – have explored what happens in melanoma cells following inhibition of BRAF.

Professor Richard Marais, who led the research, said: "BRAF inhibitors have improved survival for patients with . Unfortunately, eventual drug resistance is preventing long-term cure in most of these patients. We wanted to understand how these drugs might induce unwanted effects in melanoma cells – particularly in cells which also have a mutation in the RAS gene."

The group found that blocking BRAF activity, either using drugs or by altering a cell's genes, led to the RAS-mutated melanoma cells changing shape and becoming more invasive. These changes in behaviour would lead to metastatic spread of the disease throughout the body. Their study, published recently in the journal Science Signaling, showed that the BRAF inhibitors re-activated certain pathways within cells leading to melanoma cells becoming resistant to therapy.

"We found that we could counteract this behaviour by adding a second drug to the BRAF inhibitor – one that targets MEK. It looks like our study further supports the combined use of both BRAF and MEK inhibitors in melanoma patients," added Professor Marais.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

5 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

9 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

11 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.